HGBCL
EPCORITAMAB RECEIVES FDA APPROVAL FOR RELAPSED/REFRACTORY DLBCL
SG Tylor
The FDA has granted approval to epcoritamab-bysp (Epkinly), the first T-cellāengaging bispecific antibody, for the treatment of relapsed/refractory diffuse large ...